Non Metastatic Prostate Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Non metastatic prostate cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Non Metastatic Prostate Cancer Today - Breaking & Trending Today

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate. ....

United States , Region Flamande , San Antonio , Henar Hevia , Luca Dezzani , Exchange Commission , Janssen Research Development , American Urological Association Annual Meeting , Steering Committee , Janssen Cilag International , None Of Janssen Cilag International , European Medicines Agency , Janssen Cilag International Nv Inc , Oral Presentation Session , Urological Association Annual Meeting , Steering Committee Chair , Chief Medical Officer , Surgical Oncology , Vice President , Medical Affairs , Solid Tumour , Johnson Innovative , Senior Director , Area Lead , Innovative Medicine , Cilag International ,

SonaCare Medical Announces Significant Publication of Focal Therapy Comparison to Radical Therapy

SonaCare Medical Announces Significant Publication of Focal Therapy Comparison to Radical Therapy
January 28, 2021
CHARLOTTE, NC, UNITED STATES, January 28, 2021 /EINPresswire.com/ SonaCare Medical, LLC, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to report the publication of Focal Therapy Compared to Radical Prostatectomy for Non-Metastatic Prostate Cancer: A Propensity Score-Matched Study(1) just released in Nature. In this analysis, focal therapy and radical prostatectomy were compared using 1-to-1 propensity score-matched for treatment year, age, PSA, Gleason, T-Stage, cancer core length and neoadjuvant hormone use. At 3, 5 and 8 years Failure Free Survival (FFS) for radical prostatectomy was 86%, 82% and 79% compared to 91%, 86% and 83% FFS for focal therapy at the same time intervals. Also, of note the secondary treatment rates were approximately 16% for radical prostatectomy and approximately 17% for ....

New York , United States , Hashim Ahmed , Karen Cornett , Surgery Inc , Sonacare Medical , Focal Therapy Compared , Radical Prostatectomy , Non Metastatic Prostate Cancer , Propensity Score Matched Study , Failure Free Survival , Vice President , Clinical Operations , Professor Hashim Ahmed , Care Medical , Focus Surgery , Internet News Presswire , Editorial Guidelines , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , கரேன் கார்னெட் , அறுவை சிகிச்சை இன்க் , அல்லாத மெட்டாஸ்டேடிக் ப்ராஸ்டேட் புற்றுநோய் , தோல்வி இலவசம் பிழைப்பு , துணை ப்ரெஸிடெஂட் , மருத்துவ செயல்பாடுகள் ,